3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Prostatic Neoplasms
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Tongue Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Endometrial Stromal
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Melanoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Fibrosarcoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Bone Neoplasms
1
Bone Diseases
1
Interventions
Paclitaxel
96
Carboplatin
81
Bevacizumab
62
Gemcitabine
36
liposomal doxorubicin
32
pembrolizumab
30
Topotecan
26
olaparib
23
Taxes
23
niraparib
17
Immunoglobulin G
17
Disulfides
17
Docetaxel
16
Cyclophosphamide
16
Cisplatin
14
Nivolumab
11
rucaparib
10
durvalumab
10
Doxorubicin
9
Albumin-Bound Paclitaxel
8
sargramostim
7
pazopanib
7
fludarabine phosphate
7
fludarabine
7
avelumab
7
Magnetic Resonance Spectroscopy
7
Ifosfamide
7
epacadostat
6
Trabectedin
6
Sorafenib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Ovarian Neoplasms
×
saracatinib
×
Clear all
NCT01196741
2015-05-05
SaPPrOC
University College, London
Phase 2/3
Completed
107 enrolled
17 charts
NCT00610714
2012-12-18
OVERT-1
AstraZeneca
Phase 2
Completed
211 enrolled
12 charts